Urelumab
- Generic Name
- Urelumab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 934823-49-1
- Unique Ingredient Identifier
- 230902QLLC
- Background
Urelumab has been used in trials studying the treatment of Leukemia, Multiple Myeloma, Malignant Tumors, and Cancer - Solid Tumors and B-Cell Non-Hodgkin's Lymphoma. Urelumab is a fully human antibody that targets CD137. The antibody product was developed using Medarex's UltiMAb(R) technology and was the first UltiMAb- derived antibody in clinical developmen...
- Associated Conditions
- -
- Associated Therapies
- -
Stereotactic Body Radiotherapy (SBRT) Plus Immunotherapy for Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-02-13
- Last Posted Date
- 2023-02-16
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 60
- Registration Number
- NCT03431948
- Locations
- 🇺🇸
University of Chicago Medical Center, Chicago, Illinois, United States
Study of Urelumab in Subjects With Advanced and/or Metastatic Malignant Tumors
- First Posted Date
- 2015-08-27
- Last Posted Date
- 2020-05-18
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 18
- Registration Number
- NCT02534506
- Locations
- 🇯🇵
Local Institution, Kobe-shi, Hyogo, Japan
Platform Study of Neoadjuvant and Adjuvant Immunotherapy for Patients With Resectable Adenocarcinoma of the Pancreas
- Conditions
- Interventions
- First Posted Date
- 2015-05-22
- Last Posted Date
- 2024-12-06
- Target Recruit Count
- 76
- Registration Number
- NCT02451982
- Locations
- 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
Urelumab (CD137 mAb) With Rituximab for Relapsed, Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL) Patients
- First Posted Date
- 2015-04-20
- Last Posted Date
- 2016-12-06
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT02420938
A Phase I Open Label Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2014-09-30
- Last Posted Date
- 2017-11-01
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 44
- Registration Number
- NCT02252263
- Locations
- 🇪🇸
Local Institution, Pamplona, Navarra, Spain
🇺🇸The Ohio State University, Columbus, Ohio, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.